Tamanoi Lab Webpage

UCLA Home | CNSI Home | MIMG Home

Publications

Protein Lipidation Inhibitors - related publications 2000-Present

  1. Lu L, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F.  In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I.   Molecular Cancer Therapeutics  2009 Epub ahead of print 

  2. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F. Inhibitors of protein geranylgeranyltransferase-I and rab geranylgeranyltransferase identified from a library of allenoate derived compounds.   J Biol Chem.  2008 Jan 28.

  3. Khazak V, Kato-Stankiewicz J, Tamanoi F, and Golemis E.A.  Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction.   Methods in Enzymology.  2005;407:612-29.

  4. Gau GL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L, Tamanoi F.  Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.   Mol Cancer Ther.  2005 Jun;4(6):918-26.

  5. Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y.  A tagging-via-substrate technology for detection and proteomics of farnesylated proteins.   Proc Natl Acad Sci U S A.  2004 Aug 24;101(34):12479-84. Epub 2004 Aug 12.

  6. Clarke S, Tamanoi F.  Fighting cancer by disrupting C-terminal methylation of signaling proteins.   J Clin Invest.  2004 Feb;113(4):513-5.

  7. Hamasaki A, Naka H, Tamanoi F, Umezawa K, Otsuka M.  A novel metal-chelating inhibitor of protein farnesyltransferase.   Bioorg Med Chem Lett.  2003 May 5;13(9):1523-6.

  8. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, Golemis EA, Tamanoi F, Khazak V.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.   Proc Natl Acad Sci U S A.  2002 Oct 29;99(22):14398-403. Epub 2002 Oct 21.

  9. Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM.  RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer.   J Biol Chem.  2001 Nov 9;276(45):42259-67. Epub 2001 Aug 31.

  10. Pervin S, Singh R, Gau CL, Edamatsu H, Tamanoi F, Chaudhuri G.  Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer.   Cancer Res. 2001 Jun 15;61(12):4701-6.

  11. Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N.  Farnesylated proteins and cell cycle progression.   J Cell Biochem Suppl.  2001;Suppl 37:64-70. Review.

  12. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J.  Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.   Cell Mol Life Sci.  2001 Oct;58(11):1636-49. Review.

  13. Yang W, Tabancay AP Jr, Urano J, Tamanoi F.   Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant.   Mol Microbiol.  2001 Sep;41(6):1339-47.

  14. Guo W, Tamanoi F, Novick P.  Spatial regulation of the exocyst complex by Rho1 GTPase.   Nat Cell Biol. 2001 Apr;3(4):353-60.

  15. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F.  Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.  Oncogene.  2000 Jun 22;19(27):3059-68.

  16. Yang W, Urano J, Tamanoi F.  Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe.   J Biol Chem.  2000 Jan 7;275(1):429-38.



Publications by Research Area


Articles related TSC/Rheb/mTOR Signaling Pathway

Articles related to Nanodelivery

Articles related to Protein Lipidation Inhibitors